Health policy and drug finance in Poland: Budget impact analysis.

Ewa Orlewska M.D., Ph.D.
Background

Budget impact analysis (BIA) estimates the financial consequences of adoption and diffusion of a new health intervention within a specific health care setting or system context. In particular, such analysis predicts how a change in the mix of pharmaceuticals or other therapies used to treat a specific disease will impact the trajectory of health spending on that condition. In contrast to a cost-effectiveness analysis (CEA), which measures the value of new interventions in terms of monetary units per additional unit of health benefit (e.g., dollars per quality-adjusted life year gained) to estimate their economic efficiency, BIA serves the very humble, pragmatic goal of examining “affordability”, the chief concern of health managers everywhere.
Program

Moderator:

Valentin Brodszky, M.D. Ph.D.
Corvinus University of Budapest, Health Economics and Health Technology Assessment Research Centre

16:30 – 16:40 Inaugural

Prof. György Jenei, Corvinus University of Budapest, Department of Public Policy and Management

16:40 – 17:30

Ewa Orlewska M.D. Ph.D., Centre for Pharmacoeconomics, Warsaw, Poland.

Health policy and drug finance in Poland: Budget impact analysis.

Abstract

Over the years budget impact analysis (BIA) have taken back seat to cost-effectiveness analysis (CEA) and researchers in the field of economic evaluation had paid little attention to methodological development of BIA. The recognition that comprehensive economic assessment of a new healthcare intervention requires both CEA and BIA has led to increased interest in estimation of the financial and healthcare service impact of adopting the new therapy. BIA serves the very humble, pragmatic goal of examining “affordability”, the chief concern of health managers everywhere. Therefore BIA should be positioned as complementary to CEA and viewed as working in parallel in helping to decide how best to allocate scarce healthcare resources.

17:30 – 18:50 Discussion

19:00 Afterwords

Valentin Brodszky M.D. Ph.D.
Corvinus University of Budapest, Health Economics and Health Technology Assessment Research Centre
Ewa Orlewska M.D., Ph.D.

Ewa Orlewska M.D. Ph.D., doctor of medical science - employed at the Centre for Pharmacoeconomics in Warsaw. She authored textbooks in pharmacoeconomics, drafts of guidelines for carrying out pharmacoeconomic analysis, financial analysis and cost calculation in the economic assessment of health care programmes. She published works on pharmacoeconomic issues in Polish and foreign scientific journals. Chief editor of "Farmakoekonomika" journal, a member of the ISPOR Budget Impact Task Force, the ISPOR Drug Cost Task Force - European Subgroup and the National Network Leaders Committee on Health Economics (iHEA).

Selected publications: